Patrick A Ott

Summary

Affiliation: New York University School of Medicine
Country: USA

Publications

  1. ncbi request reprint Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma
    Patrick A Ott
    Division of Medical Oncology, New York University Cancer Institute, New York University School of Medicine, New York, NY 10016, USA
    Chemotherapy 55:221-7. 2009
  2. ncbi request reprint Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment
    Patrick A Ott
    New York University Cancer Institute, Division of Medical Oncology, 160 E 34th Street, New York, NY 10016, USA
    Immunotherapy 3:213-27. 2011
  3. doi request reprint Vemurafenib and radiation therapy in melanoma brain metastases
    Ashwatha Narayana
    Department of Radiation Oncology, New York University Langone Medical Center, 566 First Avenue HC 107, New York, NY 10016, USA
    J Neurooncol 113:411-6. 2013
  4. doi request reprint Enrollment in clinical trials correlates with improved survival in metastatic melanoma
    Nagashree Seetharamu
    Department of Medicine, New York University School of Medicine, New York, NY, USA
    Oncology 81:403-9. 2011
  5. ncbi request reprint Ipilimumab for patients with advanced mucosal melanoma
    Michael A Postow
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 18:726-32. 2013
  6. ncbi request reprint Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma
    Patrick A Ott
    Department of Medical Oncology, New York University School of Medicine, New York, NY, USA
    Invest New Drugs 31:425-34. 2013
  7. doi request reprint Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial
    Patrick A Ott
    Division of Medical Oncology, NYU Cancer Institute, New York University School of Medicine, New York, NY 10016, USA
    Cancer Chemother Pharmacol 71:183-91. 2013
  8. pmc Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node
    Michelle W Ma
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA
    Mod Pathol 25:1000-10. 2012
  9. pmc A phase II trial of sorafenib in metastatic melanoma with tissue correlates
    Patrick A Ott
    Department of Medical Oncology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 5:e15588. 2010
  10. pmc Mucosal melanomas: a case-based review of the literature
    Nagashree Seetharamu
    NYU Cancer Institute, 160E 34th Street, New York, New York 10016, USA
    Oncologist 15:772-81. 2010

Detail Information

Publications15

  1. ncbi request reprint Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma
    Patrick A Ott
    Division of Medical Oncology, New York University Cancer Institute, New York University School of Medicine, New York, NY 10016, USA
    Chemotherapy 55:221-7. 2009
    ..This phase II study evaluated the efficacy and tolerability of dacarbazine in combination with thalidomide in metastatic melanoma patients...
  2. ncbi request reprint Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment
    Patrick A Ott
    New York University Cancer Institute, Division of Medical Oncology, 160 E 34th Street, New York, NY 10016, USA
    Immunotherapy 3:213-27. 2011
    ....
  3. doi request reprint Vemurafenib and radiation therapy in melanoma brain metastases
    Ashwatha Narayana
    Department of Radiation Oncology, New York University Langone Medical Center, 566 First Avenue HC 107, New York, NY 10016, USA
    J Neurooncol 113:411-6. 2013
    ..This retrospective study suggests that melanoma patients with brain metastases harboring BRAF mutation appear to be a distinct sub-group with a favorable response to vemurafenib and radiation therapy and acceptable morbidity...
  4. doi request reprint Enrollment in clinical trials correlates with improved survival in metastatic melanoma
    Nagashree Seetharamu
    Department of Medicine, New York University School of Medicine, New York, NY, USA
    Oncology 81:403-9. 2011
    ..The aim of our study was to identify the factors associated with long-term survival and to determine the impact of clinical trial enrollment on patient outcome...
  5. ncbi request reprint Ipilimumab for patients with advanced mucosal melanoma
    Michael A Postow
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 18:726-32. 2013
    ..Durable responses to ipilimumab were observed, but the overall response rate was low. Additional investigation is necessary to clarify the role of ipilimumab in patients with mucosal melanoma. ..
  6. ncbi request reprint Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma
    Patrick A Ott
    Department of Medical Oncology, New York University School of Medicine, New York, NY, USA
    Invest New Drugs 31:425-34. 2013
    ..Although no RECIST responses were observed, the encouraging rate of SD in uveal melanoma patients indicates that it may be worthwhile to evaluate ADI-PEG 20 in this melanoma subgroup...
  7. doi request reprint Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial
    Patrick A Ott
    Division of Medical Oncology, NYU Cancer Institute, New York University School of Medicine, New York, NY 10016, USA
    Cancer Chemother Pharmacol 71:183-91. 2013
    ..The combination of oblimersen, a bcl-2 antisense oligonucleotide, and dacarbazine lead to superior progression-free survival in advanced melanoma patients. Albumin-bound paclitaxel (nab-paclitaxel) has single-agent activity in melanoma...
  8. pmc Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node
    Michelle W Ma
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA
    Mod Pathol 25:1000-10. 2012
    ..025) and melanoma-specific (P=0.014) survival. Our results support an assessment of local immune profiles in both the primary tumor and sentinel lymph node to help guide therapeutic decisions...
  9. pmc A phase II trial of sorafenib in metastatic melanoma with tissue correlates
    Patrick A Ott
    Department of Medical Oncology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 5:e15588. 2010
    ..Sorafenib monotherapy in patients with metastatic melanoma was explored in this multi-institutional phase II study. In correlative studies the impact of sorafenib on cyclin D1 and Ki67 was assessed...
  10. pmc Mucosal melanomas: a case-based review of the literature
    Nagashree Seetharamu
    NYU Cancer Institute, 160E 34th Street, New York, New York 10016, USA
    Oncologist 15:772-81. 2010
    ....
  11. doi request reprint Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery
    Maya Mathew
    Department of Radiation Oncology, New York University Langone Medical Center, New York, New York 10016, USA
    Melanoma Res 23:191-5. 2013
    ..In this retrospective study, administration of ipilimumab neither increased toxicity nor improved intracerebral disease control in patients with limited brain metastases who received SRS...
  12. doi request reprint Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties
    Patrick A Ott
    New York University Cancer Institute, New York University School of Medicine, 522 First Avenue, SRB 1303, New York, NY, 10016, USA
    Cancer Immunol Immunother 62:811-22. 2013
    ..Targeting both MEK and BRAF has shown efficacy in BRAF(V600) mutant melanoma...
  13. pmc A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma
    Patrick A Ott
    Department of Medical Oncology, New York University Cancer Institute, New York, New York, United States of America
    PLoS ONE 5:e8714. 2010
    ....
  14. doi request reprint Surgical approach to primary cutaneous melanoma
    Patrick A Ott
    Division of Medical Oncology, Department of Medicine, New York University School of Medicine, New York University Cancer Institute, 160 East 34th Street, 9th Floor, New York, NY 10016, USA
    Surg Oncol Clin N Am 20:39-56. 2011
    ..The treating surgeon must balance preservation of oncologic principles, with optimization of functional and aesthetic outcome. This article reviews the rationale behind the surgical approach in the patient with a primary melanoma...
  15. doi request reprint Novel therapeutics for melanoma
    Nagashree Seetharamu
    NYU Cancer Institute, New York University Medical Center, New York, NY 10016, USA
    Expert Rev Anticancer Ther 9:839-49. 2009
    ..These novel therapeutics offer hope for this aggressive and so far largely treatment-resistant disease. In this review we will discuss some of the most promising novel therapeutic agents for advanced melanoma...